Bayer HealthCare (BYR.L,BAYRY.PK,BAYZF.PK) and Onyx Pharmaceuticals Inc. (ONXX) announced that the U.S. Food and Drug Administration or FDA approved Bayer's Stivarga (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy).
Bayer stated that the approval of Stivarga is based on results from the pivotal Phase III study or CORRECT that demonstrated improvement in overall survival or OS and progression-free survival or PFS compared to placebo in patients with mCRC whose disease had progressed after approved standard therapies.
Stivarga is a Bayer compound developed by Bayer. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc. under which Onyx will receive a royalty on any future global net sales of Stivarga in oncology. Bayer and Onyx will jointly promote Stivarga in the United States, Bayer said.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.